|
Outcome of the Treatment of Retinopathy of
Prematurity in Qatar
El Shafei M.M., Rodriguez V.R., Martinez
F.E.
Ophthalmology Section, Department of Surgery,
Hamad Medical Corporation
Doha, Qatar
 Abstract:
To evaluate the
results of the treatment of Retinopathy of
Prematurity (ROP) patients in Qatar a
retrospective analysis was made of 43 infants
treated between January 1999 and December 2002
initially with indirect laser transpupillary
photocoagulation. Cryotherapy was used only on
those needing re-treatment. A favorable outcome
overall was obtained in 40 cases (90%) after ten
received re-treatment. The statistical
interpretation, complicating factors and
outcomes are discussed. It is concluded that the
results of threshold ROP treatment in Qatar are
encouraging.
  Introduction:
Retinopathy of prematurity (ROP), first
described in 1942 (1),
is a multifactorial proliferative retinopathy
which occurs almost exclusively in premature
infants. Many risk factors and associated
conditions have been suggested and reported, the
most significant being low birth weight, lower
gestational age and the need for supplemental
oxygen.
The incidence of ROP
has been closely related to the improvement in
neonatal care. For about the last 15 years, a
fetus with a gestational age of 25 weeks and/or
a birth weight of 700 grams has more than a 50 %
probability of survival(2).
Hence the population at risk for developing ROP
has increased. It is known that in newborns of
less than 1700 grams birth weight the incidence
of ROP reaches 50.9 % and 4.7 % of them develop
end-stage disease(3).
If there were no treatment for this disease the
consequences would be devastating. In a survey
carried out in schools for the blind as many as
39 % of cases of blindness or severe visual
impairment have been found to be due to ROP(4).
Nevertheless, with the increased awareness and
improved life support capabilities at Neonatal
Intensive Care Units (NICU), along with
treatment for threshold ROP disease, this figure
has been reduced(5).
As a result of
newborn immaturity, large areas of the retina
are avascular, presumably producing an ischemic
mediated release of angiogenic factors causing a
neovascular response(6).
Destruction of these non-vascularized zones
could be a rationale for removing this
triggering condition.
Attempts at treating
ROP started in 1968. After the International
Classification of ROP (IC ROP) improved the
understanding of the nature of the disease, and
the utilization of screening eye examination for
ROP detection, a multicenter trial of
cryotherapy for ROP was carried out,
demonstrating the efficacy of cryoablation in
reducing the risk of an unfavorable outcome in
newborns with “threshold” ROP(7).
Later, laser photocoagulation proved to be as
effective as cryotherapy(8),
even becoming an important alternative when zone
I treatment was needed.
In 1997 the
Ophthalmology Section, Surgery Department in
Hamad Medical Corporation, Doha, Qatar, began a
screening program for premature infants as well
as treatment of threshold ROP. As soon as the
first cases of threshold ROP were detected,
cryotherapy was performed. In 1999 a laser
indirect ophthalmoscope was received and was
used immediately to apply this technique to
these infants. The results of the treated
patients are reported and analyzed below.
  Patients
and Methods:
The charts were reviewed retrospectively of 46
infants with a birth weight (BW) of 1500 grams
or less and a gestational age (GA) of 32 weeks
or less admitted to Hamad Hospital Neonatal
Intensive Care Unit (NICU) between 1st January
1999 and 31st December 2002. These were
screened, diagnosed and staged for ROP based on
the criteria and recommendations of the ICROP
Study (9)
(Table 1) and were treated with
laser photocoagulation for threshold ROP. Of the
46, three were excluded because of insufficient
follow-up data (6.52 %); one died three days
after treatment as a result of systemic
complications unrelated to the treatment, and
two left the country soon after treatment.
Finally 43 infants were analyzed (Graph 1).
|
Table 1:
Study Definitions
|
|
Graph 1: Study design and
general results
|
|
*ILOP = Indirect Laser
Ophthalmoscope Photocoagulation
|
Infants eligible for
treatment were those with threshold disease as
Cryo-ROP Study criteria(10)
(Table 1). A detailed parental
informed consent was required before treatment.
Diode laser photocoagulation was used within 48
hours of diagnosis of the condition. The use of
a lid speculum and pupillary dilatation was
always necessary. For dilatation purposes, we
used an infant mydriatic drops mixture prepared
in our pharmacy (phenylephrine 1%, tropicamide
0.45 % and cyclopentolate 0.45 %) applied twice
with a 15 minute interval. Treatment was applied
always by two of the authors (MME and VRR) only
to the whole avascular retinal zone anterior to
the ridge and up to the ora serrata.
|
Table 2:
Baseline Characteristic of Sample
|
A diode laser unit
with indirect ophthalmoscope delivery system
(IRIS Oculight Slx LIO 500, IRIS Medical
Instruments; Mountain View, CA; USA) and an
aspheric 20 diopters Volk lens, with scleral
indentation (when needed) were used. Laser spots
were placed one-half “burn width” apart, with a
faint white endpoint laser mark. Laser power
range was 200 to 500 mW; duration of single
applications was 200 msec.; Burn numbers ranged
from 801-1216, with an average of 978.
Re-treatment using
cryotherapy was necessary when no regression or
non-treated areas with residual activity were
discovered during the early follow-up. Several
applications, with retinal whitening as an
endpoint, and a freeze time of about 2-3 seconds
was the chosen technique. A 2 mm diameter
neonatal cryoprobe (DORC. Ophthalmic Cryounit,
Spembly Medical Ltd. Hampshire, UK) was
used. The mean number of cryo applications was
seven (range 4-9). No cases needed conjunctival
incision for application of the treatment.
Treatment was
carried out always in the operating theatre at
Hamad Hospital under general anesthesia
consisting of anticholinergic premedication to
stop oculocardiac reflex and a
narcotic-relaxation technique to maintain the
cardio-respiratory stability with monitoring by
a neonatologist and anesthetist. The treatment
was halted temporarily if that was requested by
the medical support team due to the child’s
condition becoming medically unstable. Post
surgery treatment consisted of combined
antibiotic and steroid eye drops three times a
day for three days.
Treatment was
followed up after 24 hours and then every week
until total regression of the disease was
achieved. Re-treatment was considered if no
signs of regression were detected two weeks
after the initial treatment. If full regression
was achieved, follow-up visits were scheduled at
three, six and twelve months of age. At the age
of one year patients were re-examined again
under general anesthesia and refraction was
performed (data not analyzed).
Only two categories
of treatment outcome were considered: favorable
or unfavorable (Table 1). Baseline
independent variables such as birth weight (BW),
gestational age (GA) at birth, post-conceptional
age (PCA), presence of systemic complications
(not related to the surgical event) and also the
clinical characteristics of the disease (zones
involved and extension of neovascularization)
were analyzed. For statistical analysis of this
retrospective study, descriptive statistics (%,
mean, SD) were used for baseline
clinical-demographic variables. To evaluate the
possible influences of baseline variables and
disease characteristic on treatment outcome, a
correlation test (r) was performed. For outcome
categories analysis, unpaired T Student’ test
for continuous variables and chi-square test for
non-continuous were applied. Level of
significance was assumed for an
a
value of 0.
05.
  Results:
Forty three infants (86 eyes) with a diagnosis
of bilateral symmetrical threshold ROP were
treated in HMC-NICU during the period. There
were no statistical differences regarding gender
or nationality on treated patients (p> 0.5).
Mean GA was 26.2 weeks, and mean BW was 811
grams. Mean PCA at ROP Threshold diagnosis and
treatment was 35 weeks (Table 2). Mean interval
time between diagnosis and treatment was 1.8
days. Laser treatment was applied initially to
all patients. Ten infants (23.25%) needed
re-treatment by cryo application (Graphic
1).
“Favorable” outcome with regression of ROP was
achieved in 40 patients (93.02%), 33 of them
(76.64 %) after the initial treatment. Only
three infants (6.97%) did not show regression,
even after re-treatment (Graphic 1).
Regression of plus disease occurred within one
week in all infants. Mean time span between
treatment and ROP regression or other
characteristics of a favorable outcome was 16.3
days (range 13-18).
Cryotherapy was the selected method for
re-treatment of ten patients, seven of whom
(70%) showed a favorable outcome. Regression
mean time was shorter than in the primary
treatment but the difference was not
significant. Most common causes for re-treatment
were the presence of “skipped” previously
untreated areas (4 out of 10) and/or
insufficient regression after first applications
(6 out of 10).
No local (ocular) complications occurred during
laser treatment. In the case of cryotherapy,
only mild chemosis and periorbital swelling
after the applications were noticed, without any
sequels. No systemic complications occurred
during the procedures or related to them.
“Unfavorable” outcomes occurred in three
patients after re-treatment due to residual
neovascular activity. Two developed tractional
retinal detachment (one stage 4B and the other
stage 5 with vitreous hemorrhage). The third
patient regressed from acute ROP but developed a
gross retinal fold that reached the macula.
Comparative analysis of favorable and
unfavorable outcomes is characterized by the
very small number of failed cases. Nevertheless,
important differences were noticed in variables
such as gestational age (GA) (p=0.01), presence
of infant’s systemic complications (p=0.008) and
presence of ROP disease in zone I (p= 0.0003)
(Table 3). Regarding the last two
variables, 11 of 40 infants had systemic
complications in the favorable group (and all
three in the unfavorable group); and only two of
40 had ROP in Zone I in the favorable group (and
two of the three in the unfavorable group). Mean
birth weight (BW), post-conceptional age (PCA)
at threshold’s disease diagnosis, and ROP
extension failed to show significant differences
between the outcome groups (p>0.05).
|
Table 3: Treatment Outcome and
Baseline Clinical Data
|
|
BW =
Birth Weight PCA = Post
Conceptional Age GA =
Gestational Age
(+) = Mean
(-) = Statistically Significant
(X2 Test)
(*) - Statistically Significant
(T' Student Test) |
However, when baseline variables were
re-analyzed, particularly stratified and
correlated with the presence of an “unfavorable”
outcome (Table 4), some were found
to be statistically significantly related with
this event. The presence of BW lower than 800
grams, GA less than 27 weeks, presence of
systemic complications and ROP on zone I were
statistically correlated with failed outcome (p<
0.05). The strongly correlated variables were
the presence of systemic complications (r=0.82)
and the GA (r=0.73).
|
Table 4 : Perinatal Risk Factors
Correlated with Unfavorable Outcome
(Only Statistically Significant
Results r ; p < 0.05)
|
  Discussion:
The IC ROP and the Cryo-ROP study defined the
natural history, the necessity and the
effectiveness of ROP treatment. Despite the fact
that the laser era for the treatment of ROP
appeared later, these studies have become the
“golden standard” when ROP is focused on the
clinical setting.
Our series showed no differences when comparing
it with the Cryo ROP Study regarding BW and GA
(p>0.05) (11)
but our range
of favorable outcomes was greater than the Cryo
ROP Study (93.02 % vs. 74.4 %). This remarkable
difference could basically be the result of some
particularities of our series. Despite having no
differences in BW (811 g. vs. 800 g) or GA (26.2
vs. 26.3 weeks) with the Cryo ROP series, there
were twice the number of newborn infants with
threshold ROP in zone I (9.30 % vs. 4.12%).
Assuming that this ROP characteristic was
statistically correlated with treatment failure,
it seems that the large success ratio was
definitely influenced by the treatment used. All
our patients were treated with laser
photocoagulation and it is well known that the
presence of threshold ROP in zone I reveals
particular conditions regarding outcome when
treatment is focused on(12-15)
because of
the easier accessibility of posterior areas of
the retina with the laser. Even more, this
difference in outcome becomes much less
significant when this series is compared with
other studies in which laser photocoagulation is
used with similar structural design and outcome
evaluation. For example, in the McNamara(16)
and Fleming(17)
series, there
were no differences with our patients in BW or
GA, and the success ratio was similar. Also, in
the Hunter study there were similar results(18).
Laser
photocoagulation has already become the
preferred treatment for threshold ROP because of
its many advantages and effectiveness even in
severe cases(19-21).
A laser indirect
ophthalmoscope became available in our
department in 1999 since when it has become the
preferred treatment. The learning curve was
short for experienced surgeons and the
complications are less than for cryotheraphy.
Despite the potential of immediate complications
as inadvertent macular burns, posterior segment
hemorrhages at all levels and thermal injuries
to the cornea, iris and lens, local (ocular)
complications are fewer and less significant.
Conjunctival hematomas, scarring or lacerations,
all reported in Cryo-ROP studies, are much less
frequent with laser treatment(21).
Induced myopia after treatment is more common
with cryotherapy than with laser treatment(22,23)
and
retino-choroidal scarring caused by cryotherapy
is also reduced with the potential advantage of
lower incidence of rhegmatogenous retinal
detachment.
Nevertheless laser
treatment is not totally harmless; excessive
treatment cause thermal damage to the inner
scleral tissues and ciliary nerves and vessels
and the incidence of cataract after treatment
appears to be greater when compared with
cryotherapy(24).
Fortunately, in this series there were none of
these complications with laser treatment.
Cryotherapy has some
advantages in its application because it
requires a less clear optical status (including
corneal or lens opacities, and vitreous or
pre-retinal hemorrhages, which are frequent in
severe cases) and it can still be applied even
when the pupil is poorly dilated. Since most of
our patients with an insufficient first
treatment procedure needed retinal ablation
mostly in the far periphery, an easily
accessible area with the cryoprobe, cryotherapy
was the preferred method for retreatment.
In our study all the
patients in the unfavorable outcome group
required re-treatment as a result of an
insufficient first therapeutic approach. It is
known that light treatment with laser may not
affect the spindle cell endothelial capillary
precursors of the inner retinal layers, which,
in the immature retina, may affect the course of
ROP as a potentially triggering factor for
neovascularisation(25).
All the treatments
were conducted under general anesthesia in the
presence of a neonatologist and an anesthetist
using anticholinergic premedication and a
narcotic relaxation technique to maintain
cardiorespiratory stability. At the same time
the immobility of the infant during the
procedure was guaranteed. We believe that the
management of those immature infants under these
care conditions is ideal. In comparison with
other reports(26),
we did not have any systemic treatment-related
complications.
The influence of
some baseline general and ocular conditions in
the final outcome was variable. Nevertheless,
the presence of severe systemic complications in
newborn infants with ROP, whether or not it was
related with the treatment procedure, had a
significant influence. Episodes of hypoxemia,
long term oxygen supplementation, hypocarbia,
sepsis, blood transfusion or ventricular
hemorrhages, are, among others, well known risk
factors for developing severe ROP(27,28).
In this study we restricted the analysis to the
presence or absence of severe, life-threatening
systemic complications. About thirty per cent of
the infants were presented with severe systemic
complications unrelated to treatment including
all three of the unfavorable outcome group.
Considering that ROP is a multifactorial
disease, many neonatal risk factors other than
the most important ones (gestational age and
birth weight) may play a significant role,
although they are not fully understood. They
could also have an influence on the outcome of
treatment. However, caution should be taken when
interpreting or assuming conclusions based on
the characteristics our unfavorable outcome
group because it contained only three patients.
Despite some limitations in this series, such as
the relatively short follow-up, very encouraging
results have been achieved since the start of
ROP screening and treatment Hamad Medical
Corporation. The World Health Organization
“Vision 2020 Program” has identified ROP as an
important cause of blindness in both high and
middle income countries(29).
Consequently, the long term visual results
(beyond the scope of this study) and the impact
on the incidence of child blindness surely will
be very important in the Qatari society and
health plans.
 References:
1.
Hopkins A, Shorvon SD. Definition and
epidemiology of epilepsy. In: eds. Hopkins A,
Shorvon SD, Caseino C, eds. Epilepsy. 2nd
edition. London: Chapman and Hall, 1995;1-24.
1.
Terry TL: Extreme prematurity and fibroblastic
overgrowth of persistent vascular sheath behind
crystalline lens. I. Preliminary report. Am J
Ophthalmol 1942; 25: 203-204.
2.
Hack M, Fanaroff AA: Outcome of extremely-low
birth weight infants between 1982 & 1988. N Eng
J Med 1989; 321: 1642-47.
3.
Fielder AR, Shaw DE, Robinson J, Ng YK: Natural
history of ROP. A prospective study. Eye 1992;
6: 233-42.
4.
Gilbert C, Rahi J, Eckstein M, et al:
Retinopathy of Prematu- rity in middle-outcome
countries. Lancet. 1997; 350: 12-14.
5.
Termote J, Schalij-Delfos NE, Brouwers HAA,
Donders ART, Cats BP: New developments in
neonatology: Less severe retinopathy of
prematurity? J Pediatr Ophthalmol and Strabismus
2000; 37; 142- 48.
6.
Phepls DL. Retinopathy of premturity. In:
Neonatal-Perinatal Medicine. Two. Eds. Fanaroff
AA and Martin RJ. Mosby, St. Louis, MO. 2002:
4443-59.
7.
Cryotherapy for Retinopathy of Prematurity
Cooperative Group. Multicentre Trial of
Cryotherapy for Retinopathy of Prematurity:
one-year outcome- structure and function. Arch
Ophthalmol 1990; 108: 1406-16.
8.
The Laser ROP Study Group: Laser therapy for
retinopathy of prematurity. Arch Ophthalmol
1994; 112: 154-56.
9.
The Committee for the Classification of
Retinopathy of Prematurity. An International
Classification of Retinopathy of Prematurity.
Arch Ophthalmol 1984; 102: 1130-34.
10.
The Cryotherapy for Retinopathy of Prematurity
Cooperative Group. Multicenter Trial of
Cryotherapy for Retinopathy of Prematurity:
preliminary results. Arch Ophthalmol 1988; 106:
471-79.
11.
The Cryotherapy for Retinopathy of Prematurity
Cooperative Group. Incidence and Early Course of
Retinopathy of Prematurity. Ophthalmol 1991; 98:
1628-40.
12.
Mc Gregor ML, Wherley AJ, Fellows RR, Bremer DL,
Rogers GL, Letson AD: A comparison of
cryotherapy versus diode laser photocoagulation
in 100 consecutive infants treated for
retinopathy of prematurity. JAAPOS 1998; 82:
360-64.
13.
Connolly BP, Mc Namara A, Regillo CD, Tasman W,
Sharma S: Visual outcomes after laser
photocoagulation for threshold retinopathy of
prematurity. Ophthalmol 1999; 106: 1734-38.
14.
Capone A, Diaz-Rohena R, Sternberg P Jr, et al:
Diode laser photocoagulation for zone I
threshold retinopathy of prematurity. Am J
Ophthalmol 1993; 116: 444-50.
15.
Axel-Siegel R, Snic M, Cottear D et al: Diode
laser treatment of posterior retinopathy of
prematurity. Br J Ophthalmol 2000; 84:
1383-1386.
16.
McNamara JA, Tasman W, Brown GC, Federman JL:
Laser photocoagulation for threshold retinopathy
of prematurity. Arch ophthalmol 1991; 109:
1342-43.
17.
Fleming T, Runge P, Charles S: Diode laser
photocoagulation for threshold, posterior
retinopathy of prematurity. Am J Ophthalmol
1992; 114: 589-92.
18.
Hunter DG, Repka MX: Diode laser
photocoagulation for threshold retinopathy of
prematurity. A randomized study. Ophthalmology
1993; 100: 238-44.
19.
Brooks SE, Johnson M, Wallace DK, et al:
Treatment outcome in fellows eyes after laser
photocoagulation for retinopathy of prematurity.
Am J Ophthalmol 1999; 127: 56-61.
20.
Banach MJ, Ferrone PJ, Tresse MT: A comparison
of dense versus less dense diode laser
photocoagulation patterns for threshold
retinopathy of prematurity. Ophthalmol 2000;
107: 324-27.
21.
Banach MJ, Beristein DM: Laser therapy for
retinopathy of prematurity. Curr Opin Ophthalmol
2001, 12: 164-170.
22.
O’Keefe M, O’Reilly J, Laningan B: Long-term
visual outcome of eyes with retinopathy of
prematurity with cryotherapy or diode laser. Br
J Ophthalmol 1998; 82: 1246-48.
23.
Kent D, Pennie F, Zaurus D; et al: The influence
of retinopathy of prematurity on ocular growth.
Eye 2000; 14: 23-29.
24.
Lambert SR, Capone Jr. A, Cingle K et al.
Cataract and phthisis bulbi after laser
photoablation for threshold retino- pathy of
prematurity. Am J Ophthalmol 2000; 129: 585-91.
25.
Kretzer FL, Mehta RS, Johnson AT, et al. Vitamin
E protects against retinopathy of prematurity
through action on spindle cells. Nature 1984;
309: 793-5.
26.
Brown GC, Tasman WS, Naidoff M, et al: Systemic
complica- tions associated with retinal
cryoablation for retinopathy of prematurity.
Ophthalmology 1990; 97: 855-58.
27.
Wheatley CM, Dickinson JL, Mackey DA, Craig JE,
Sale MM: Retinopathy of prematurity: recent
advances in our understanding. Br J Ophthalmol
2002; 86: 696-701.
28.
Ganesh A, Nair M, Mitra S: Retinopathy of
Prematurity. An Update. Saudi J Ophthalmol.
2001; 15 (3): 203-20.
29.
Steinkuller PG, Du L Gilbert C, et al: Childhood
blindness. J AAPOS 1999; 3: 26-32.
|